37284938|t|Ceftriaxone improves impairments in synaptic plasticity and cognitive behavior in APP/PS1 mouse model of Alzheimer's disease by inhibiting extrasynaptic NMDAR-STEP61 signaling.
37284938|a|Abnormal activation of the extrasynaptic N-methyl-d-aspartate receptor (NMDAR) contributes to the pathogenesis of Alzheimer's disease (AD). Ceftriaxone (Cef) can improve cognitive impairment by upregulating glutamate transporter-1 and promoting the glutamate-glutamine cycle in an AD mouse model. This study aimed to investigate the effects of Cef on synaptic plasticity and cognitive-behavioral impairment and to unravel the associated underlying mechanisms. We used an APPswe/PS1dE9 (APP/PS1) mouse model of AD in this study. Extrasynaptic components from hippocampal tissue homogenates were isolated using density gradient centrifugation. Western blot was performed to evaluate the expressions of extrasynaptic NMDAR and its downstream elements. Intracerebroventricular injections of adeno-associated virus (AAV)-striatal enriched tyrosine phosphatase 61 (STEP61 ) and AAV-STEP61 -shRNA were used to modulate the expressions of STEP61 and extrasynaptic NMDAR. Long-term potentiation (LTP) and Morris water maze (MWM) tests were performed to evaluate the synaptic plasticity and cognitive function. The results showed that the expressions of GluN2B and GluN2BTyr1472 in the extrasynaptic fraction were upregulated in AD mice. Cef treatment effectively prevented the upregulation of GluN2B and GluN2BTyr1472 expressions. It also prevented changes in the downstream signals of extrasynaptic NMDAR, including increased expressions of m-calpain and phosphorylated p38 MAPK in AD mice. Furthermore, STEP61 upregulation enhanced, whereas STEP61 downregulation reduced the Cef-induced inhibition of the expressions of GluN2B, GluN2BTyr1472 , and p38 MAPK in the AD mice. Similarly, STEP61 modulation affected Cef-induced improvements in induction of LTP and performance in MWM tests. In conclusion, Cef improved synaptic plasticity and cognitive behavioral impairment in APP/PS1 AD mice by inhibiting the overactivation of extrasynaptic NMDAR and STEP61 cleavage due to extrasynaptic NMDAR activation.
37284938	0	11	Ceftriaxone	Chemical	MESH:D002443
37284938	86	89	PS1	Gene	19164
37284938	90	95	mouse	Species	10090
37284938	105	124	Alzheimer's disease	Disease	MESH:D000544
37284938	153	158	NMDAR	Gene	14810
37284938	159	165	STEP61	Gene	84867
37284938	218	247	N-methyl-d-aspartate receptor	Gene	14810
37284938	249	254	NMDAR	Gene	14810
37284938	291	310	Alzheimer's disease	Disease	MESH:D000544
37284938	312	314	AD	Disease	MESH:D000544
37284938	317	328	Ceftriaxone	Chemical	MESH:D002443
37284938	330	333	Cef	Chemical	MESH:D002443
37284938	347	367	cognitive impairment	Disease	MESH:D003072
37284938	426	435	glutamate	Chemical	MESH:D018698
37284938	436	445	glutamine	Chemical	MESH:D005973
37284938	458	460	AD	Disease	MESH:D000544
37284938	461	466	mouse	Species	10090
37284938	521	524	Cef	Chemical	MESH:D002443
37284938	552	583	cognitive-behavioral impairment	Disease	MESH:D003072
37284938	667	670	PS1	Gene	19164
37284938	672	677	mouse	Species	10090
37284938	687	689	AD	Disease	MESH:D000544
37284938	891	896	NMDAR	Gene	14810
37284938	1002	1034	enriched tyrosine phosphatase 61	Gene	
37284938	1036	1042	STEP61	Gene	84867
37284938	1053	1059	STEP61	Gene	84867
37284938	1108	1114	STEP61	Gene	84867
37284938	1133	1138	NMDAR	Gene	14810
37284938	1321	1327	GluN2B	Gene	14812
37284938	1396	1398	AD	Disease	MESH:D000544
37284938	1399	1403	mice	Species	10090
37284938	1405	1408	Cef	Chemical	MESH:D002443
37284938	1461	1467	GluN2B	Gene	14812
37284938	1568	1573	NMDAR	Gene	14810
37284938	1610	1619	m-calpain	Gene	12334
37284938	1639	1647	p38 MAPK	Gene	26416
37284938	1651	1653	AD	Disease	MESH:D000544
37284938	1654	1658	mice	Species	10090
37284938	1673	1679	STEP61	Gene	84867
37284938	1711	1717	STEP61	Gene	84867
37284938	1745	1748	Cef	Chemical	MESH:D002443
37284938	1790	1796	GluN2B	Gene	14812
37284938	1818	1826	p38 MAPK	Gene	26416
37284938	1834	1836	AD	Disease	MESH:D000544
37284938	1837	1841	mice	Species	10090
37284938	1854	1860	STEP61	Gene	84867
37284938	1881	1884	Cef	Chemical	MESH:D002443
37284938	1971	1974	Cef	Chemical	MESH:D002443
37284938	2008	2039	cognitive behavioral impairment	Disease	MESH:D003072
37284938	2047	2050	PS1	Gene	19164
37284938	2051	2053	AD	Disease	MESH:D000544
37284938	2054	2058	mice	Species	10090
37284938	2109	2114	NMDAR	Gene	14810
37284938	2119	2125	STEP61	Gene	84867
37284938	2156	2161	NMDAR	Gene	14810
37284938	Association	MESH:D000544	12334
37284938	Positive_Correlation	MESH:D002443	12334
37284938	Negative_Correlation	MESH:D002443	MESH:D000544
37284938	Association	MESH:D000544	84867
37284938	Negative_Correlation	MESH:D002443	14812
37284938	Positive_Correlation	MESH:D002443	MESH:D005973
37284938	Negative_Correlation	MESH:D002443	14810
37284938	Positive_Correlation	14812	84867
37284938	Positive_Correlation	MESH:D000544	14812
37284938	Negative_Correlation	MESH:D002443	26416
37284938	Association	MESH:D002443	84867
37284938	Positive_Correlation	26416	84867
37284938	Association	MESH:D005973	MESH:D018698
37284938	Association	MESH:D000544	26416
37284938	Association	MESH:D000544	14810
37284938	Positive_Correlation	MESH:D002443	MESH:D018698
37284938	Association	14810	84867
37284938	Positive_Correlation	MESH:D002443	MESH:D003072

